ARMP

Armata Pharmaceuticals Inc. [ARMP] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ARMP Stock Summary

Top 10 Correlated ETFs

ARMP

Top 10 Correlated Stocks

ARMP

In the News

ARMP Financial details

Company Rating
-
Market Cap
117.48M
Income
-72.19M
Revenue
4.53M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
66
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.84
Forward P/E
-
PEG
-0.22
P/S
-
P/B
-9.32
P/C
-
P/FCF
-2.1
Quick Ratio
1.48
Current Ratio
1.67
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2
EPS next Y
-
EPS next Q
-
EPS this Y
76.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
24.73%
EPS Q/Q
-36.05%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-56%
ROE
-384%
ROC
-0.46%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.07-5.26
52W High
-72.4%
52W Low
+38%
RSI
25
Rel Volume
0.18
Avg Volume
16.33K
Volume
2.94K
Perf Week
-17.86%
Perf Month
-31.34%
Perf Quarter
-38.94%
Perf Half Y
-41.53%
-
-
-
-
Beta
0.701
-
-
Volatility
0.09%, 0.22%
Prev Close
-5.48%
Price
1.38
Change
-13.75%

Something similar

Top by Market Cap
VTI
TSLA
GOOG
CMC.DE
3V64.DE
Top Correlated ETFs
EDEN
BSMR
BSMQ
ESIH.L
BSMT
Top Correlated Stocks
BEN.PA
0752.HK
HPOL-B.ST
002212.SZ
603033.SS
Similar Market Cap
PRTK
2017.HK
ALCLS.PA
8446.HK
WIGTX

Company Profile

Healthcare Biotechnology
  • Volume Average 16.33K
  • Market Capitalization 117.48M
  • Employee 66
  • CEO Dr. Deborah L. Birx M.D.
  • Headquarters Marina del Rey,CA,US
  • IPO Date 1994-05-20
  • Website https://www.armatapharma.com

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.